Christopher Yasiejko
banner
yasiejko.bsky.social
Christopher Yasiejko
@yasiejko.bsky.social
Senior correspondent, IP team @BloombergLaw.com. Patents!

Past: @bloomberg.com, @nytimes.com, DelawareOnline.com. Bylines: @Inquirer.com, Phila. Daily News, @ColumJournReview.bsky.social, more.

Views=mine. Repost≠endorsement. Tips? DM me.
Reposted by Christopher Yasiejko
They were careless people, Tom and Daisy- they smashed up things and creatures and then retreated back into their money or their vast carelessness or whatever it was that kept them together, and let other people clean up the mess they had made.

-FS Fitzgerald, The Great Gatsby, published 4/10/1925.
April 10, 2025 at 12:32 PM
NEW: @novonordisk.bsky.social & @elilillyandcompany.bsky.social are using dense clusters of patents to extend monopolies on blockbuster diabetes and weight-loss drugs including #Ozempic, #Wegovy, & #Mounjaro, fueling high prices and health inequities, according to an @imakglobal.bsky.social report.
Novo, Lilly Patent Tactics Keep GLP-1 Prices High, Report Says
Novo Nordisk A/S and Eli Lilly & Co. are using dense clusters of patents to extend monopolies on blockbuster diabetes and weight-loss drugs including Ozempic, Wegovy, and Mounjaro, fueling high prices...
news.bloomberglaw.com
April 10, 2025 at 4:14 PM
Reposted by Christopher Yasiejko
“The Senate Judiciary Committee advanced a slate of bipartisan bills aimed at lowering drug prices by curbing certain patent-related tactics used by pharmaceutical companies to delay cheaper generics and biosimilars.” @yasiejko.bsky.social , @bloomberg.com
Drug Patent, Pricing Bills Approved by Senate Committee (1)
The Senate Judiciary Committee advanced a slate of bipartisan bills aimed at lowering drug prices by curbing certain patent-related tactics used by pharmaceutical companies to delay cheaper generics…
news.bloomberglaw.com
April 8, 2025 at 5:26 PM
A @danahercorporation.bsky.social unit urged a federal court to quash @amgen.bsky.social’s subpoena in a patent suit over Fresenius Kabi’s biosimilars of Prolia and Xgeva, arguing Amgen seeks confidential details about a cell-culture ingredient that would expose its trade secrets.
Danaher Unit Fights Amgen Subpoena in Fresenius Biosimilars Case
A Danaher Corp. unit urged a federal court to quash Amgen Inc.’s subpoena in a patent suit over Fresenius SE & Co.’s biosimilars of Prolia and Xgeva, arguing Amgen seeks confidential details about a c...
news.bloomberglaw.com
February 6, 2025 at 8:57 PM
MSN Laboratories is pushing to launch its generic Entresto during a brief legal window before a federal judge decides on @novartis.bsky.social‘s request to block the cheaper version of its blockbuster drug for six more months.

This blockbuster patent-infringement dispute just won't die.
Novartis Flags Legal Gap as MSN Eyes Generic Entresto Launch
MSN Laboratories Pvt. Ltd. is pushing to launch its generic Entresto during a brief legal window before a federal judge decides on Novartis AG‘s request to block the cheaper version of its blockbuster...
news.bloomberglaw.com
February 6, 2025 at 8:45 PM
Tesla and Elon Musk urged a Calif. federal judge to dismiss Alcon Entertainment’s suit accusing them of using an AI-altered image from “Blade Runner 2049" to promote Tesla's forthcoming Cybercab.

Warner Bros. Discovery hosted livestreamed promotional event & said case based on “wild assertions.”
Tesla, Musk Push to Toss 'Blade Runner' AI Image Copyright Suit
Tesla Inc. and its Chief Executive Officer Elon Musk urged a California federal judge to dismiss Alcon Entertainment LLC’s lawsuit accusing the electric carmaker of using an AI-altered image from the ...
news.bloomberglaw.com
February 6, 2025 at 8:30 PM
NEW: @10xgenomics.bsky.social and @harvard.edu's Harvard College settled w/ @vizgen.bsky.social before a federal jury could decide whether Vizgen unlawfully used patented gene-mapping technology or whether Harvard rigged the rules to give 10x a market monopoly, according to a Thursday court filing.
February 6, 2025 at 7:06 PM
SETTLED: @novartis.bsky.social & MSN Labs had been awaiting ruling on validity of 3 infringed patents after 2/2024 bench trial. Expire in 6/2028, 3/2031, and 12/2029, respectively.

Kisqali US sales = $1.678B in 2024, ~3.3% revenue & 63% 🔺than in 2023 (Novartis’ earnings report, released today).
Novartis, MSN Settle Patent Suit on Kisqali Cancer Treatments
Novartis AG and MSN Laboratories Pvt. Ltd. settled a dispute over patents for Novartis’ blockbuster Kisqali and Kisqali Femara Co-Pack, both used to treat advanced or metastatic breast cancer, accordi...
news.bloomberglaw.com
January 31, 2025 at 10:06 PM
My first foray into @bsky.app:

Curio Bioscience's counterclaim alleging anticompetitive conduct and monopolistic intent by @10xgenomics.bsky.social in a case over patented gene-expression technology should proceed, a federal magistrate judge said in a mixed report.

Click for full coverage.
Monopolization Claim Against 10x Should Proceed, Judge Says
Curio Bioscience Inc.'s counterclaim alleging anticompetitive conduct and monopolistic intent by 10x Genomics Inc. in a case over patented gene-expression technology should proceed, a federal magistra...
news.bloomberglaw.com
January 30, 2025 at 10:19 PM